Bleomycin Sulfate From Teva Parenteral With Bleomycin Sulfate Eq 30 Units Base/vial Information

The Ingredients: Bleomycin Sulfate
Dosage Form and Administration: Injectable; Injection
Drug Trade Name: Bleomycin Sulfate
Firm: Teva Parenteral
Strength: EQ 30 UNITS BASE/VIAL
New Drug Application Type: A
The Drug Application Number:65033
Medicine Product Number: 2
Approval Date: 6/27/2000
Reference Listed Drug: No
Type: RX
Applicant Full Name: Teva Parenteral Medicines Inc

Melanoma

Melanoma is a malignant tumor of melanocytes, which present in skin but also in the bowel and the eyes. It is one of the more rare types of skin cancer, but causes the majority of skin cancer-related deaths. Malignant melanoma is a serious type of skin cancer. Uncontrolled growth of pigment cells, called melanocytes cause cancer. Despite many years of intensive laboratory and clinical research, the sole effective cure for melanoma is surgical resection of the primary tumor before it achieves a Breslow thickness greater than 1mm. Each year doctors diagnose around 160,000 new cases of melanoma and it presents more frequently in males and Caucasians. It is more common in Caucasian populations living in sunny climates than other groups. According to a WHO report, about 48,000 melanoma-related deaths occur worldwide per annum.

Alcohol

Disulfiram also known as Antabuse is an aversion therapy that induces nausea when a person consumes alcohol. Acamprosate works by restoring normal balance to the glutamate neurotransmitter system in the brain, helping to reduce alcohol cravings. The Food and Drug Administration (FDA) approves the use of Naltrexone, which blocks some of the pleasurable effects of alcohol.

Infectious Diseases among Drug Abusing Offenders

It is critical for the criminal justice and drug abuse treatment systems to work together and combine efforts to reduce the spread of HIV/AIDS and other infectious diseases, which occur at higher rates among drug abusers in the criminal justice system than among the general population. The prevalence of AIDS is approximately five times higher among incarcerated offenders than in the general population. In addition, individuals in the criminal justice system represent a significant portion of hepatitis B, hepatitis C and tuberculosis cases in the United States. Although most people contract infectious diseases in the community and not in correctional settings, the correctional setting must treat these infectious diseases once diagnosed.
Infectious diseases among offenders who re-enter or live within the community present a serious public health challenge. While incarcerated, offenders often have access to adequate healthcare, which offers opportunities for integrating strategies to address medical, mental health and drug abuse problems. Doctors should link offenders with infectious diseases who return to the community with medical care facilities within the community before release. Community health, drug treatment and criminal justice agencies should work together to offer education, screening, counseling, prevention and treatment programs for HIV/AIDS, hepatitis and other infectious diseases to offenders in or returning to the community. Drug abuse treatment can decrease the spread of infectious disease by reducing risky behaviors such as needle sharing and unprotected sex.
The need to negotiate access to health services and adhere to complex treatment protocols places a large burden on the addicted offender and many offenders fall through the cracks. Untreated or deteriorating medical or mental health problems increase the risk of relapse to drug abuse and to possible arrest and incarceration, again.